{"schema_version":"1","generated_at":"2026-11-02T21:01:26.888Z","data_as_of":"2026-10-25","url":"https://www.findmykol.com/kol/andrew-hantel","json_url":"https://www.findmykol.com/kol/andrew-hantel/profile.json","record_kind":"full","profile_kind":"clinical","person":{"slug":"andrew-hantel","name":"Andrew Hantel","credential":"MD","title":"Assistant Professor of Medicine, Harvard Medical School","specialty":"Hematology / Oncology","specialty_raw":"Hematology & Oncology","therapeutic_area":"Leukemia","therapeutic_areas":["Leukemia"],"institution":"Dana-Farber Cancer Institute","institution_url":"https://www.findmykol.com/institution/dana-farber-cancer-institute","city":"Boston","state":"MA","region":{"label":"Northeast","url":"https://www.findmykol.com/region/northeast"},"country":{"name":"United States","code":"US","status":"verified"}},"identifiers":{"npi":"1023457819","orcid":"0000-0001-9612-3643","openalex":"A5069251789"},"summary":"Andrew Hantel is Assistant Professor of Medicine, Harvard Medical School at Dana-Farber Cancer Institute. OpenAlex indexes 111 publications with 1,780 citations (h-index 19); ClinicalTrials.gov lists 4 registered studies with this person as an investigator.","overview":{"text":"Andrew Hantel, M.D., is Assistant Professor of Medicine, Harvard Medical School at Dana-Farber Cancer Institute. The public record shows 111 publications with 1,780 citations (h-index 19), centered on Ethics in Clinical Research, Acute Myeloid Leukemia Research, Statistical Methods in Clinical Trials. It also documents an investigator role on 4 registered clinical trials, industry payments reported by 7 companies, 1 NIH-funded awards (2022–2026).","bullets":["Most recent indexed publication: 2026 · Journal of clinical oncology","Top research focus: Ethics in Clinical Research","4 registered trials on ClinicalTrials.gov","Open Payments reporting from 7 companies"],"generated_at":"2026-11-02"},"focus":{"indications":[{"label":"Leukemia (AML/ALL/CML/CLL)","therapeutic_area":"Oncology","trials":3,"topics":1,"strength":10},{"label":"Hematologic Neoplasms","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Breast Cancer","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Multiple Myeloma","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3}],"research_topics":["Ethics in Clinical Research","Acute Myeloid Leukemia Research","Statistical Methods in Clinical Trials","Ethics and bioethics in healthcare","Pharmaceutical Economics and Policy"],"drugs_studied":{"total":3,"shown":3,"withheld":0,"rows":[{"name":"Venclexta","generic":"Venetoclax","trials":0,"payments":8,"publications":0,"mentions":8},{"name":"Rylaze","generic":"Asparaginase","trials":0,"payments":2,"publications":0,"mentions":2},{"name":"Calquence","generic":"Acalabrutinib","trials":0,"payments":1,"publications":0,"mentions":1}]},"works_with":{"total":9,"shown":3,"withheld":6,"rows":[{"name":"Abbvie Inc.","trials":0,"payments":8,"mentions":8},{"name":"Dana-Farber Cancer Institute","trials":3,"payments":0,"mentions":3},{"name":"Jazz Pharmaceuticals Inc.","trials":0,"payments":3,"mentions":3}]}},"scholarship":{"works_count":111,"cited_by_count":1780,"h_index":19,"i10_index":33,"pubmed_count":22,"latest_activity_year":2026,"source":"works"},"trials":{"count":4,"shown":3,"withheld":1,"matched_by":"identity-adjudicated record","rows":[{"nct":"NCT07341867","title":"Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype","phase":"PHASE1","status":"RECRUITING","role":"Investigator","sponsor":"Andrew Hantel, MD","source_url":"https://clinicaltrials.gov/study/NCT07341867","trial_url":"https://www.findmykol.com/trial/NCT07341867"},{"nct":"NCT06907797","title":"Tools for Reducing Inequity in Acute Leukemia (TRIAL): Beta Testing","phase":"NA","status":"RECRUITING","role":"Investigator","sponsor":"Dana-Farber Cancer Institute","source_url":"https://clinicaltrials.gov/study/NCT06907797","trial_url":"https://www.findmykol.com/trial/NCT06907797"},{"nct":"NCT06795139","title":"Pilot of a Trial Enrollment Diversity Dashboard","phase":"NA","status":"COMPLETED","role":"Investigator","sponsor":"Dana-Farber Cancer Institute","source_url":"https://clinicaltrials.gov/study/NCT06795139","trial_url":"https://www.findmykol.com/trial/NCT06795139"}],"source":"trials"},"payments":{"company_count":7,"program_years":{"first":2023,"last":2025},"rows_total":9,"shown":3,"withheld":6,"rows":[{"payer":"JAZZ PHARMACEUTICALS INC.","program_year":2025,"amount_usd":154.72,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1023457819"},{"payer":"Genentech, Inc.","program_year":2024,"amount_usd":10000,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1023457819"},{"payer":"JAZZ PHARMACEUTICALS INC.","program_year":2024,"amount_usd":8400,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1023457819"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1023457819","source":"payments"},"funding":{"award_count":1,"fiscal_years":{"first":2022,"last":2026},"rows_total":5,"shown":3,"withheld":2,"rows":[{"project":"K08CA273043","title":"Diversifying Acute Leukemia Clinical Trial Enrollment Through Multilevel Intervention","fiscal_year":2026,"amount_usd":207900,"organization":"DANA-FARBER CANCER INST","source_url":"https://reporter.nih.gov/quickSearch/K08CA273043"},{"project":"K08CA273043","title":"Diversifying Acute Leukemia Clinical Trial Enrollment Through Multilevel Intervention","fiscal_year":2025,"amount_usd":255716,"organization":"DANA-FARBER CANCER INST","source_url":"https://reporter.nih.gov/quickSearch/K08CA273043"},{"project":"K08CA273043","title":"Diversifying Acute Leukemia Clinical Trial Enrollment Through Multilevel Intervention","fiscal_year":2024,"amount_usd":254592,"organization":"DANA-FARBER CANCER INST","source_url":"https://reporter.nih.gov/quickSearch/K08CA273043"}],"source":"grants"},"congress":{"count":31,"years":{"first":2015,"last":2026},"societies":["ASCO","ASH"],"shown":3,"withheld":28,"rows":[{"title":"When disaster strikes: A scoping review of climate-resilience toolkits relevant to cancer care delivery.","society":"ASCO","meeting":"ASCO Annual Meeting","year":2026,"role":"co_author","presentation_type":"unknown","contribution_type":"abstract","doi":"https://doi.org/10.1200/jco.2026.44.16_suppl.e23198","source_url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e23198","status":"verified"},{"title":"The impact of food and drug administration-based eligibility criteria on demographic representation in current phase III clinical trials for newly diagnosed breast cancer.","society":"ASCO","meeting":"ASCO Annual Meeting","year":2025,"role":"co_author","presentation_type":"unknown","contribution_type":"abstract","doi":"https://doi.org/10.1200/jco.2025.43.16_suppl.e23021","source_url":"https://doi.org/10.1200/jco.2025.43.16_suppl.e23021","status":"verified"},{"title":"Association between extreme heat exposures and survival in patients with multiple myeloma","society":"ASH","meeting":"ASH Annual Meeting","year":2025,"role":"co_author","presentation_type":"unknown","contribution_type":"abstract","doi":"https://doi.org/10.1182/blood-2025-2786","source_url":"https://doi.org/10.1182/blood-2025-2786","status":"verified"}],"source":"congress"},"publications":{"total":22,"shown":5,"withheld":17,"matched_by":"ORCID record, linked to PubMed","recent":[{"title":"Ethical Design and Implementation of Monetary Transfer Interventions in Clinical Cancer Research.","year":2026,"journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","types":["Journal Article"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/41894650/","status":"verified"},{"title":"Stratifying survival: the role of social determinants of health on AML outcomes by ELN 2022 criteria.","year":2026,"journal":"Blood advances","types":["Journal Article"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/41538295/","status":"verified"},{"title":"Impact of modernizing eligibility criteria on enrollment and representation in acute myeloid leukemia clinical trials.","year":2026,"journal":"Blood","types":["Journal Article"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/41100728/","status":"verified"},{"title":"Barriers and facilitators to representative acute leukemia trial participation at National Cancer Institute-designated comprehensive cancer centers.","year":2025,"journal":"The oncologist","types":["Journal Article"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/40795379/","status":"verified"},{"title":"The Duffy antigen: A narrative review of testing, epidemiology, neutrophil counts and clinical consequences.","year":2025,"journal":"British journal of haematology","types":["Journal Article","Review"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/40685916/","status":"verified"}],"most_cited":{"total":111,"shown":5,"withheld":106,"rows":[{"title":"TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes","year":2016,"cited_by_count":795,"type":"article","source_url":"https://doi.org/10.1056/nejmoa1605949"},{"title":"Analysis of very elderly (≥80 years) non‐hodgkin lymphoma: impact of functional status and co‐morbidities on outcome","year":2011,"cited_by_count":96,"type":"article","source_url":"https://doi.org/10.1111/j.1365-2141.2011.08934.x"},{"title":"Validation of a financial toxicity (FT) grading system.","year":2017,"cited_by_count":69,"type":"conference-abstract","source_url":"https://doi.org/10.1200/jco.2017.35.15_suppl.6615"},{"title":"Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab","year":2018,"cited_by_count":65,"type":"article","source_url":"https://doi.org/10.1186/s40425-018-0384-0"},{"title":"Perspectives of Oncologists on the Ethical Implications of Using Artificial Intelligence for Cancer Care","year":2024,"cited_by_count":58,"type":"article","source_url":"https://doi.org/10.1001/jamanetworkopen.2024.4077"}]},"source":"publications"},"network":{"coauthors_total":40,"shown":3,"withheld":37,"coauthors":[{"name":"Gregory Alan Abel","coauthored_works":55},{"name":"Daniel J. DeAngelo","coauthored_works":18},{"name":"Thomas P. Walsh","coauthored_works":17}],"source":"works"},"presence":{"owned_accounts":{"total":1,"shown":1,"rows":[{"platform":"doximity","url":"https://www.doximity.com/pub/andrew-hantel-md","status":"provisional"}]},"mentions":{"total":1,"shown":1,"rows":[{"url":"https://bioethics.hms.harvard.edu/faculty-staff/andrew-hantel","platform":"other","status":"provisional"}]},"verified_means":"confirmed in more than one place; provisional means found and still being confirmed"},"recognition":{"education":{"total":4,"shown":4,"rows":[{"value":"MD, Loyola University Chicago","source_url":"https://www.dana-farber.org/find-a-doctor/andrew-hantel","status":"verified","collected_at":"2026-11-02"},{"value":"MPH, Harvard School of Public Health","source_url":"https://bioethics.hms.harvard.edu/faculty-staff/andrew-hantel","status":"verified","collected_at":"2026-11-02"},{"value":"Board certified in Internal Medicine","source_url":"https://www.dana-farber.org/find-a-doctor/andrew-hantel","status":"provisional","collected_at":"2026-11-02"},{"value":"Board certified in Medical Oncology","source_url":"https://www.dana-farber.org/find-a-doctor/andrew-hantel","status":"provisional","collected_at":"2026-11-02"}]},"awards":{"total":2,"shown":2,"rows":[{"value":"Career Development Award, American Society of Clinical Oncology (2022-2025)","source_url":"https://connects.catalyst.harvard.edu/Profiles/profile/142765384","status":"provisional","collected_at":"2026-11-02"},{"value":"Research funding and award, Leukemia and Lymphoma Society (program not identified)","source_url":"https://bioethics.hms.harvard.edu/faculty-staff/andrew-hantel","status":"verified","collected_at":"2026-11-02"}]},"secondary_affiliations":{"total":1,"shown":1,"rows":[{"value":"Member, HMS Center for Bioethics","source_url":"https://bioethics.hms.harvard.edu/faculty-staff/andrew-hantel","status":"verified","collected_at":"2026-11-02"}]},"media":{"total":3,"shown":3,"rows":[{"value":"AJMC interview: \"We need to lower barriers to and burdens of trial entry: Dr. Andrew Hantel\" (August 14, 2024)","source_url":"https://www.ajmc.com/view/we-need-to-lower-barriers-to-and-burdens-of-trial-entry-dr-andrew-hantel","status":"provisional","collected_at":"2026-11-02"},{"value":"HealthTree Foundation ASH 2021 interview on disparities in AML clinical trials","source_url":"https://healthtree.org/aml/community/articles/ash2021--dr-andrew-hantel-on-understanding-and-addressing-disparities-in-aml-clinical-trials","status":"provisional","collected_at":"2026-11-02"},{"value":"Patient Empowerment Network video on post-access enrollment in AML clinical trials","source_url":"https://powerfulpatients.org/resource/why-is-post-access-enrollment-vital-in-aml-clinical-trial-participation/","status":"provisional","collected_at":"2026-11-02"}]}},"similar":[{"name":"Kenneth Anderson","slug":"kenneth-anderson","institution":"Dana-Farber Cancer Institute","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/kenneth-anderson","json_url":"https://www.findmykol.com/kol/kenneth-anderson/profile.json"},{"name":"Frank Hodi","slug":"frank-hodi","institution":"Dana-Farber Cancer Institute","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/frank-hodi","json_url":"https://www.findmykol.com/kol/frank-hodi/profile.json"},{"name":"Paul Richardson","slug":"paul-richardson","institution":"Dana-Farber Cancer Institute","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/paul-richardson","json_url":"https://www.findmykol.com/kol/paul-richardson/profile.json"},{"name":"Toni Choueiri","slug":"toni-choueiri","institution":"Dana-Farber Cancer Institute","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/toni-choueiri","json_url":"https://www.findmykol.com/kol/toni-choueiri/profile.json"},{"name":"Hagop Kantarjian","slug":"hagop-kantarjian","institution":"The University of Texas MD Anderson Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/hagop-kantarjian","json_url":"https://www.findmykol.com/kol/hagop-kantarjian/profile.json"},{"name":"Jorge Cortes","slug":"jorge-cortes","institution":"University of Alabama at Birmingham (UAB)","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/jorge-cortes","json_url":"https://www.findmykol.com/kol/jorge-cortes/profile.json"},{"name":"Ayalew Tefferi","slug":"ayalew-tefferi","institution":"Mayo Clinic","specialty":"Hematology","url":"https://www.findmykol.com/kol/ayalew-tefferi","json_url":"https://www.findmykol.com/kol/ayalew-tefferi/profile.json"},{"name":"Charles Sawyers","slug":"charles-sawyers","institution":"Memorial Sloan Kettering Cancer Center","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/charles-sawyers","json_url":"https://www.findmykol.com/kol/charles-sawyers/profile.json"}],"coverage":{"note":"An identity-adjudicated profile: every section above was checked. Where a section states a count of zero, the public record was searched and nothing was found."},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"trials":1,"payments":6,"funding":2,"congress":28,"publications":17,"network":37}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts","collected_at":"2026-11-02"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies","collected_at":"2026-11-02"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2023 to 2025","collected_at":"2026-11-02"},"grants":{"name":"NIH RePORTER","url":"https://reporter.nih.gov","provides":"Federally funded research awards, by fiscal year","collected_at":"2026-11-02"},"congress":{"name":"OpenAlex","url":"https://openalex.org","provides":"DOI-verified congress abstracts across AACR, ASCO, ASH, ASTRO, ESMO","disclaimer":"Congress abstracts are published as DOI-bearing journal supplements and attributed via the same ORCID-disambiguated authorship as publications.","collected_at":"2026-11-02"},"publications":{"name":"PubMed (NLM)","url":"https://pubmed.ncbi.nlm.nih.gov","provides":"Peer-reviewed publications, linked to the PubMed record","collected_at":"2026-11-02"}},"methodology_url":"https://www.findmykol.com/about#methodology"}